175 related articles for article (PubMed ID: 16033730)
1. Optimized Basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with Basal insulin glargine.
Garg SK; Rosenstock J; Ways K
Endocr Pract; 2005; 11(1):11-7. PubMed ID: 16033730
[TBL] [Abstract][Full Text] [Related]
2. Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096).
Ratner R; Wynne A; Nakhle S; Brusco O; Vlajnic A; Rendell M
Diabetes Obes Metab; 2011 Dec; 13(12):1142-8. PubMed ID: 21812890
[TBL] [Abstract][Full Text] [Related]
3. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes.
Rave K; Klein O; Frick AD; Becker RH
Diabetes Care; 2006 Aug; 29(8):1812-7. PubMed ID: 16873785
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial.
Testa MA; Gill J; Su M; Turner RR; Blonde L; Simonson DC
J Clin Endocrinol Metab; 2012 Oct; 97(10):3504-14. PubMed ID: 22851487
[TBL] [Abstract][Full Text] [Related]
5. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes.
Rayman G; Profozic V; Middle M
Diabetes Res Clin Pract; 2007 May; 76(2):304-12. PubMed ID: 17113676
[TBL] [Abstract][Full Text] [Related]
6. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
Heller S; Koenen C; Bode B
Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
[TBL] [Abstract][Full Text] [Related]
7. Microneedle-based intradermal versus subcutaneous administration of regular human insulin or insulin lispro: pharmacokinetics and postprandial glycemic excursions in patients with type 1 diabetes.
Pettis RJ; Hirsch L; Kapitza C; Nosek L; Hövelmann U; Kurth HJ; Sutter DE; Harvey NG; Heinemann L
Diabetes Technol Ther; 2011 Apr; 13(4):443-50. PubMed ID: 21355716
[TBL] [Abstract][Full Text] [Related]
8. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial.
Heine RJ; Van Gaal LF; Johns D; Mihm MJ; Widel MH; Brodows RG;
Ann Intern Med; 2005 Oct; 143(8):559-69. PubMed ID: 16230722
[TBL] [Abstract][Full Text] [Related]
9. Incidence of severe nocturnal hypoglycemia in patients with type 1 diabetes treated with insulin lispro or regular human insulin in addition to basal insulin glargine.
Brunetti P; Muggeo M; Cattin L; Arcangeli A; Pozzilli P; Provenzano V; Francesconi A; Calatola P; Santeusanio F
Nutr Metab Cardiovasc Dis; 2010 Sep; 20(7):519-26. PubMed ID: 19703761
[TBL] [Abstract][Full Text] [Related]
10. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine.
Bergenstal RM; Johnson M; Powers MA; Wynne A; Vlajnic A; Hollander P; Rendell M
Diabetes Care; 2008 Jul; 31(7):1305-10. PubMed ID: 18364392
[TBL] [Abstract][Full Text] [Related]
11. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
Robbins DC; Beisswenger PJ; Ceriello A; Goldberg RB; Moses RG; Pagkalos EM; Milicevic Z; Jones CA; Sarwat S; Tan MH
Clin Ther; 2007 Nov; 29(11):2349-64. PubMed ID: 18158076
[TBL] [Abstract][Full Text] [Related]
12. Comparison of dinner with bedtime administration of insulin glargine in type 1 diabetic patients treated with basal-bolus regimen.
Grimaldi A; Vialettes B; Blayo A; Brun JM; Halimi S
Diabetes Metab; 2007 Apr; 33(2):121-8. PubMed ID: 17276718
[TBL] [Abstract][Full Text] [Related]
13. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart.
Vague P; Selam JL; Skeie S; De Leeuw I; Elte JW; Haahr H; Kristensen A; Draeger E
Diabetes Care; 2003 Mar; 26(3):590-6. PubMed ID: 12610006
[TBL] [Abstract][Full Text] [Related]
14. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
Jacober SJ; Scism-Bacon JL; Zagar AJ
Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
[TBL] [Abstract][Full Text] [Related]
15. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
Hollander P; Cooper J; Bregnhøj J; Pedersen CB
Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
[TBL] [Abstract][Full Text] [Related]
16. Effects of multiple daily injection therapy with Humalog mixtures versus separately injected insulin lispro and NPH insulin in adults with type I diabetes mellitus.
Roach P; Bai S; Charbonnel B; Consoli A; Taboga C; Tiengo A; Bolli G;
Clin Ther; 2004 Apr; 26(4):502-10. PubMed ID: 15189747
[TBL] [Abstract][Full Text] [Related]
17. Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.
Rosenstock J; Guerci B; Hanefeld M; Gentile S; Aronson R; Tinahones FJ; Roy-Duval C; Souhami E; Wardecki M; Ye J; Perfetti R; Heller S;
Diabetes Care; 2016 Aug; 39(8):1318-28. PubMed ID: 27222510
[TBL] [Abstract][Full Text] [Related]
18. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.
Philotheou A; Arslanian S; Blatniczky L; Peterkova V; Souhami E; Danne T
Diabetes Technol Ther; 2011 Mar; 13(3):327-34. PubMed ID: 21291333
[TBL] [Abstract][Full Text] [Related]
19. Rate of Change of Premeal Glucose Measured by Continuous Glucose Monitoring Predicts Postmeal Glycemic Excursions in Patients With Type 1 Diabetes: Implications for Therapy.
Majithia AR; Wiltschko AB; Zheng H; Walford GA; Nathan DM
J Diabetes Sci Technol; 2018 Jan; 12(1):76-82. PubMed ID: 28868899
[TBL] [Abstract][Full Text] [Related]
20. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.
Esposito K; Ciotola M; Maiorino MI; Gualdiero R; Schisano B; Ceriello A; Beneduce F; Feola G; Giugliano D
Ann Intern Med; 2008 Oct; 149(8):531-9. PubMed ID: 18936501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
